Dasatinib and Quercetin (D+Q) are the most studied senolytic agents. Although they can effectively act as single drugs, their combined use has been shown to selectively target a wider range of senescent cells. In this way, together and administered intermittently, they have shown positive results in inducing apoptosis in senescent cells. This chapter comprehensively examines their efficacy, selectivity, as well as their positive and adverse effects in different models, revealing both their therapeutic potential and limitations. While D+Q treatment has demonstrated benefits in certain age-related conditions and specific cell types, its effects vary significantly depending on the senescence inducer, tissue type, and age. Moreover, their efficacy is often cell-type dependent, producing different outcomes between males and females. Before drugs like D+Q can be used to eliminate senescent cells, it is crucial to consider issues of heterogeneity, including individual drug response and sex-dependent differences. Additional clinical studies must be carried out before these drugs can be made available to the public.